1H24 Indicative Financial highlights (unaudited):

• Total global revenue including BARDA was A$48.8m, up 65.6% on STLY of A$29.5m.
• Record 1H24 sales of A$42.2m up 54.9% on STLY of A$27.3m.
• U.S. 1H24 sales of A$32.2m up 41.7% on STLY of A$22.8m.
• Rest of World sales of $A10.0m up 122.2% on STLY of A$4.5m including strong performances in ANZ, UKI, and the Middle East, also growing sales in India, Hong Kong, and Canada.
• BARDA revenue of $A4.9m up 133.1% on STLY of $A2.1m. Currently 83 patients enrolled in pivotal clinical trial.
• EBITDA, EBIT and NPAT all positive. EBITDA $1.9m, up $4.4m on STLY EBITDA ($2.5m)
• Underlying EBITDA $3.6m (excl. non-cash items)

Chairman, David Williams said: “While I view profit as a ‘nice to have’, I am more excited by the significant near-term revenue growth possibilities from our expanding geographic footprint and the new ways surgeons have found to use our products. Profits will drop naturally out of the drive and success in expanding our geographies and products. All that aside, what I didn’t expect so soon was an entry into Turkey, Middle East, Ukraine, and Israel. The humanitarian side to our business, especially in conflict zones, is strong and enormously satisfying. What was not anticipated was charities, unrelated governments, and other paying for us to supply BTM to conflict zones.”

Chief Executive Officer, Swami Raote said: “Thanks to our Clinicians enthusiastically adopting NovoSorb BTM as the next generation Standard of Care and supporting us in Peer-to-Peer education, we are able to generate a strong flywheel impact in terms of reaching and healing patients. We are now available in 37 countries, having touched and healed over 37,000 patient lives globally, across a range of clinical spectrum. Simultaneously, our surgeons are actively engaged in contributing to our innovation pipeline for graftable and implantable range of products. Lastly, I am proud of how our organisation is responding and executing and satisfied with where we are today, but preparing ourselves for a massive unmet need of redefining healing for many more across world.”